Lead Product(s): APR-OD031
Therapeutic Area: Genetic Disease
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
First mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine fluctuations.